Visitors Now: | |
Total Visits: | |
Total Stories: |
Story Views | |
Now: | |
Last Hour: | |
Last 24 Hours: | |
Total: |
Many investors are worried about the effects of Obamacare on their health insurance, quality of medical care and the economy. But one health care sub-sector that is booming despite the proposed changes is the biotechnology industry.
Biotech has always been a niche piece of many growth investors’ portfolios, but with the blossoming of the ETF industry you now have access to these cutting edge companies in just a single fund. So far this year biotech is one of the leading sectors in terms of absolute performance which is why it’s a perfect way to diversify your portfolio in a sector that continues to add alpha.
Large Cap Biotech
The largest ETF in the biotech sector is the iShares Biotech ETF (IBB). The fund currently has $2.88 billion in total assets spread among 120 companies with an expense ratio of 0.48%. The top three holdings in IBB include: Regeneron Pharmaceuticals (REGN), Gilead Sciences Inc. (GILD), and Amgen Inc. (AMGN). Together these three companies make up approximately 26% of the fund.
Read More: http://economicrisis.com/beat-obamacare-with-these-biotech-etfs/5585